Features Partner Sites Information LinkXpress
Sign In
Demo Company

Nanoparticle Therapy Reduces Plaque Inflammation and Lowers Risk of Heart Attack or Stroke

By BiotechDaily International staff writers
Posted on 06 Feb 2014
Print article
Image: A novel HDL nanoparticle (red) loaded with a statin drug, specifically targets and locally treats inflammatory macrophage cells (green) hiding inside high-risk plaque within blood vessels (Photo courtesy of Mount Sinai Medical Center).
Image: A novel HDL nanoparticle (red) loaded with a statin drug, specifically targets and locally treats inflammatory macrophage cells (green) hiding inside high-risk plaque within blood vessels (Photo courtesy of Mount Sinai Medical Center).
Reconstituted HDL (high-density lipoprotein) nanoparticles were used to transport inflammation-retarding statins to atherosclerotic plaques where the drug acted to reduce arterial blockage that could cause heart attack or stroke.

Inflammation is a key feature of atherosclerosis and a target for therapy. While statins are known to have potent anti-inflammatory properties, they cannot be exploited fully as an oral statin therapy due to low systemic bioavailability.

Investigators at Mount Sinai School of Medicine (New York, NY, USA) sought to concentrate the anti-inflammatory benefits of statins by incorporating them into nanoparticles that would accumulate at sites of inflammation within the blood vessels. For this purpose, they designed an injectable reconstituted high-density lipoprotein (rHDL) nanoparticle carrier vehicle capable of delivering statins directly to atherosclerotic plaques.

They reported in the January 20, 2014, online edition of the journal Nature Communications that they had initially demonstrated the anti-inflammatory effect of statin-rHDL in vitro and showed that this effect was mediated through the inhibition of the mevalonate pathway. They also applied statin-rHDL nanoparticles in vivo in an apolipoprotein E-knockout mouse model of atherosclerosis and showed that the nanoparticles accumulated in atherosclerotic lesions in which they directly affected plaque macrophages. Finally, they demonstrated that a three-month low-dose statin-rHDL treatment regimen inhibited plaque inflammation progression, while a one-week high-dose regimen markedly decreased inflammation in advanced atherosclerotic plaques.

“Not only could the HDL nanotherapy potentially avert repeat heart attacks, it may also have the power to reduce recurrent strokes caused by clots in brain arteries, ” said senior author, Dr. Willem Mulder, associate professor of radiology at Mount Sinai School of Medicine. “We envision that a safe and effective HDL nanotherapy could substantially lower cardiovascular events during the critical period of vulnerability after a heart attack or stroke. While we have much more to do to confirm clinical benefit in patients, our study shows how this nanotherapy functions biologically, and how this novel concept could potentially also work in the clinical setting to solve a critical problem. This nanotherapy would be the first of its kind.”

The optimum use for HDL-statin nanotherapy would be by injection following treatment of an arterial clot. The HDL nanoparticle would deliver the statin directly to macrophages that are driving the inflammatory response. “This could potentially and very rapidly stabilize a dangerous situation,” said Dr. Mulder. “In addition, after discharge, patients would continue to use their oral statins to control LDL in their blood.”

Related Links:

Mount Sinai School of Medicine

Print article



view channel
Image: Left: Green actin fibers create architecture of the cell. Right: With cytochalasin D added, actin fibers disband and reform in the nuclei (Photo courtesy of the University of North Carolina).

Actin in the Nucleus Triggers a Process That Directs Stem Cells to Mature into Bone

A team of cell biologists has discovered why treatment of mesenchymal stem cells (MSCs) with the mycotoxin cytochalasin D directs them to mature into bone cells (osteoblasts) rather than into fat cells... Read more


view channel

Molecular Light Shed on “Dark” Cellular Receptors

Scientists have created a new research tool to help find homes for orphan cell-surface receptors, toward better understanding of cell signaling, developing new therapeutics, and determining causes of drug side-effects. The approach may be broadly useful for discovering interactions of orphan receptors with endogenous, naturally... Read more

Lab Technologies

view channel
Image: The new ambr 15 fermentation micro-bioreactor system was designed to enhance microbial strain screening applications (Photo courtesy of Sartorius Stedim Biotech).

New Bioreactor System Streamlines Strain Screening and Culture

Biotechnology laboratories working with bacterial cultures will benefit from a new automated micro bioreactor system that was designed to enhance microbial strain screening processes. The Sartorius... Read more


view channel

Purchase of Biopharmaceutical Company Will Boost Development of Nitroxyl-Based Cardiovascular Disease Drugs

A major international biopharmaceutical company has announced the acquisition of a private biotech company that specializes in the development of drugs for treatment of cardiovascular disease. Bristol-Myers Squibb Co. (New York, NY, USA) has initiated the process to buy Cardioxyl Pharmaceuticals Inc. (Chapel Hill, NC, USA).... Read more
Copyright © 2000-2015 Globetech Media. All rights reserved.